Targazyme, Inc., formerly known as America Stem Cell, Inc., is a privately held biotechnology company dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cell transplants. The Company is engaged in the development of stem cell enabling technologies and the key technology platforms — ASC-101 and ASC-201 — are designed to improve the engraftment of stem cells to target organs and increase their therapeutic potential. Hematopoietic stem cells derived from cord blood, peripheral blood, and bone marrow are used to treat 70+ diseases today. ASC-101 and ASC-201 hold the promise for increasing the efficacy of these treatments for cancer patients. Additionally, these technologies have potential for many other clinical applications such as treatment of inflammation from chemotherapy/radiation, treatment of cancer tumors, auto-immune diseases and myocardial infarction.Founded in 2005, ASC is led by an experienced management team and has established a prominent board of advisors to guide its technology development programs. The Company has established a number of strategic partnerships with medical research institutions including the University of Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation, and VidaCord Technologia Biomedica.